Adherence to European Society of Cardiology Guideline-directed Medical Therapies for Patients With Chronic Heart Failure in France (GDMTs)

Sophie NISSE-DURGEAT

Status: Completed

Conditions: Care Management, Patient; Remote Monitoring; Heart Failure With Reduced Ejection Fraction; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure

Study type: Observational

Funder types: Industry

Identifiers

NCT07022379

2024-REMOTE-HF

Details and patient eligibility

About

The goal of this observational study was to evaluate trends and determinants of SGLT2 inhibitor (SGLT2i) prescriptions in heart failure patients from 2021 to 2024, particularly in relation to LVEF subgroups and evolving scientific evidence (EMPEROR-Preserved, DELIVER, 2023 Guidelines).

Participant population were adults with heart failure using the Satelia®Cardio web application to remotely monitor their condition.

The main questions it aims to answer are:

• to compare the prescription of treatments (including doses, and distribution of patients according to various therapeutic classes recommend for heart failure) with ESC recommendations to see to what extent GDMTs are adhered to.
• to quantify the association between the presence of treatments and the risk of alerts/hospitalizations and overall death and as a function of LVEF using telemonitoring.
• to evaluate the adherence across patient profiles and cardiologist practices (outpatient vs. hospital-based).

Participants will complete follow-up, quality-of-life and patient support questionnaires and provide data regarding their treatments on the web application.

Full description

A retrospective, multicenter descriptive study was conducted in France from January 1, 2021 to December 31, 2024. The REMOTE-HF study included 17,551 patients enrolled in remote monitoring program for heart failure (HF) management. We described and analyzed the implementation of ESC guidelines in patients monitored remotely with a web application named Satelia®Cardio (NP Medical).

Key clinical parameters such as age, gender, NYHA class, LVEF, and HF etiology were analyzed. Prescribed therapies including ACEi/ARB/ARNis, beta-blockers, MRAs, and SGLT2 inhibitors, were compared against the European Society of Cardiology (ESC) guideline-directed medical therapies (GDMTs).

Adherence was evaluated across patient profiles and cardiologist practices (outpatient vs. hospital-based) in France.

Enrollment: 17,551 patients

Sex: All

Ages: 18 to 105 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• registered to use Satelia®Cardio to remotely monitor their condition
• patients diagnosed with heart failure whatever the aetiology:

Especially patients who undergone:

Hospitalization within the previous 12 months, OR patients with NYHA class II or more, and BNP > 100 pg/ml OR NT-proBNP > 1000 pg/ml.

Exclusion criteria

• People aged under 18 years old
• Pregnant women
• Physical or psychological impossibility for the patient or carer to use the digital medical device according to the judgment of the doctor wishing to include the patient in the remote medical monitoring project.

Trial design

17,551 participants in 1 patient group

Heart failure patients remotely monitored with Satelia® Cardio program with SGLT2i treatment

Description:

Heart failure patients remotely monitored with Satelia® Cardio program without SGLT2i treatment